Abstract 1278P
Background
The first interim analysis of the phase 3 INSPIRE study (NCT04632758) (data cutoff: Nov 13, 2022) showed that iruplinalkib significantly improved PFS versus crizotinib in patients (pts) with advanced ALK+ and ALK TKI-naïve NSCLC. Here we present updated survival and safety results after additional follow-up.
Methods
Pts with ALK+, stage IIIB/IV NSCLC naïve to ALK TKI were randomized (1:1) to oral iruplinalkib 180 mg QD (7-day run-in at 60 mg QD) or crizotinib 250 mg BID. The primary endpoint was PFS assessed by Independent Review Committee (IRC) per the RECIST version 1.1. Secondary endpoints included PFS by investigator (INV), OS and safety.
Results
From Sep 4, 2019 to Dec 2, 2020, 292 pts were randomized (iruplinalkib/crizotinib, n=143/149). The data cutoff date of this updated analysis was Oct 25, 2023. Median follow-up for PFS by IRC was 35.02 months for iruplinalkib and 34.96 months for crizotinib. Median PFS by IRC was 36.80 months for iruplinalkib and 14.55 months for crizotinib (HR, 0.311 [98.02% CI, 0.222-0.436]; stratified one-sided log-rank p<0.0001). Other efficacy results are presented in the table. Incidence of ≥ grade 3 treatment-related AEs was 53.1% for iruplinalkib and 51.0% for crizotinib.
Conclusions
These results demonstrated iruplinalkib continued to improve PFS versus crizotinib in pts with advanced ALK+ and ALK TKI-naïve NSCLC. The safety profile was consistent with prior results and no new safety findings was observed. Table: 1278P
Updated survival results of iruplinalkib versus crizotinib
| Iruplinalkib (n=143) | Crizotinib (n=149) | |
| mPFS by INV, mo (95% CI) | 31.11 (23.98-38.60) | 14.75 (11.10-16.56) |
| HR (95% CI) | 0.423 (0.312-0.573) | |
| mPFS in ALK+ pts by IRC, mo (95% CI) | 45.90 (28.32-NE) | 14.55 (11.07-16.53) |
| HR (95% CI) | 0.292 (0.199-0.430) | |
| mPFS in pts with baseline CNS metastases by IRC, mo (95% CI) | 26.25 (18.27-NE) | 11.01 (7.46-14.72) |
| HR (95% CI) | 0.215 (0.103-0.449) | |
| mPFS in pts without baseline CNS metastases by IRC, mo (95% CI) | 45.90 (29.50-NE) | 16.39 (12.88-18.30) |
| HR (95% CI) | 0.330 (0.222-0.489) | |
| 36-mo OS rate (%) (95% CI) | 81.3 (73.8-86.9) | 75.8 (67.8-82.1) |
Note: ALK+ pts were those whose ALK status was confirmed positive by both central laboratory and local hospitals.
Clinical trial identification
NCT04632758.
Editorial acknowledgement
Legal entity responsible for the study
Qilu Pharmaceutical Co., Ltd.
Funding
Qilu Pharmaceutical Co., Ltd.
Disclosure
M. Si, H. Li, L. Li, X. Kang: Other, Personal, Full or part-time Employment: Qilu Pharmaceutical Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
1244P - Association of tumor-draining lymph node metastatic patterns and neoadjuvant immunochemotherapy effectiveness in resectable non-small cell lung cancer
Presenter: Yu-heng Zhou
Session: Poster session 05
1245P - Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy vs. neoadjuvant chemotherapy in lung cancer treatment: A mixed method meta-analysis based on global randomized controlled trials
Presenter: Yiyang Li
Session: Poster session 05
Resources:
Abstract
1246P - PIT-3: A multicenter phase II trial of erlotinib induction followed by surgery in stage IIIA (N2) EGFR mutated non-small cell lung cancer
Presenter: Kazuya Takamochi
Session: Poster session 05
1247P - Radiotherapy (RT) patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients (pts) with Stage III unresectable non-small cell lung cancer (UR-NSCLC) treated with durvalumab (D) after chemoradiotherapy (CRT)
Presenter: Andrea Riccardo Filippi
Session: Poster session 05
1248P - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: LAURA China cohort analysis
Presenter: Xiaorong Dong
Session: Poster session 05
1249P - Health-related quality of life (HRQoL) at diagnosis for unresectable stage III NSCLC: Results from the French nationwide prospective study OBSTINATE (GFPC 06-2019)
Presenter: Charles Ricordel
Session: Poster session 05
1250P - Impact of systemic treatment on cardiac events following chemoradiotherapy in stage III lung cancer patients
Presenter: Judit Sanz Beltran
Session: Poster session 05
1251P - Retrospective evaluation of inflammatory biomarkers in patients affected by unresectable stage III NSCLC: Final results of NEUTRALITY trial
Presenter: Emanuela Olmetto
Session: Poster session 05
1252P - Stage III non-small cell lung cancer (NSCLC) in France, characteristics treatments and survival results of French real-world data
Presenter: Olivier Molinier
Session: Poster session 05